B Cell Lymphoma
From the Journals
Zanubrutinib may be poised to challenge ibrutinib for CLL
The phase 1 study had a 96% overall response rate and there were no dose-limiting toxicities.
Conference Coverage
Ibrutinib/rituximab effective, safe as frontline treatment for older patients with MCL
LUGANO, SWITZERLAND –The chemotherapy-free combination was associated with a high objective response rate in patients with a median age of 71...
From the Journals
Low-dose radiation therapy looks effective in hard-to-treat MCL
The treatment approach can be used safely with concurrent chemotherapy.
From the Journals
ICYMI: Ibrutinib/rituximab combo improves CLL survival
Progression-free and overall survival were superior in patients receiving ibrutinib and rituximab, compared with standard chemotherapy.
From the Journals
BTK mutations linked to CLL progression on ibrutinib
The findings support mutational analysis in CLL patients on ibrutinib, according to researchers.
News
FDA approves rituximab biosimilar for cancer, autoimmune disorders
The biosimilar is approved for certain cancers and autoimmune disorders, although, like its reference drug, it comes with a boxed warning from the...
Conference Coverage
Chemo-free combo gets high response rate in relapsed or refractory DLBCL
LUGANO, SWITZERLAND – Lenalidomide plus the anti-CD19 antibody tafasitamab was associated with a 60% overall response rate.
From the Journals
Ibrutinib-venetoclax found highly active in hard-to-treat CLL
Trial results suggest the two drugs may have synergistic efficacy when used together, and raise the possibility of achieving MRD negativity with...
From the Journals
CAR T-cell therapy less effective in transformed follicular lymphoma
The complete response rate and duration of response were better in patients with follicular lymphoma than in those with transformed follicular...
From the Journals
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCL
The researchers said the findings cast doubt on the ability of this CDK inhibitor to be effective in B-cell lymphomas.
From the Journals
Intravenous CNS chemo looks best for testicular DLBCL
Intrathecal chemotherapy did not offer a benefit, according to findings from the retrospective analysis of patients with testicular diffuse large...